The PaceNew therapies / indications available since the last 12 months 
Imbruvica®
BY: Jasper ChanJun 16, 2015

Imbruvica®
(Ibrutinib)  Janssen

 

Composition:

• New formulation available as tablet containing 140 mg of ibrutinib

 

Indication(s):

• As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
 

• As a single agent or in combination with rituximab or obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
 

• As a single agent or in combination with bendamustine and rituximab (BR) for the treatment of adult patients with CLL who have received at least one prior therapy

 

• As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy

 

• In combination with rituximab for the treatment of adult patients with WM

 

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.

You May Be Interested In
Omacor
BY: Olive TseDec 20, 2021
MOUNJARO®
BY: Eura SoJun 20, 2024
Revolade
BY: Olive TseJun 15, 2020
Rocuronium B. Braun
BY: Olive TseDec 20, 2021